Patents Examined by Howard V. Owens
-
Patent number: 7169768Abstract: A method of decreasing atherosclerosis and its complications including but not limited to myocardial infarction, stroke and peripheral vascular disease wherein the method involves administering to a human or an animal an amount of an inhibitor of the release of LHRH or GnRH.Type: GrantFiled: June 3, 1998Date of Patent: January 30, 2007Inventors: Kenneth M. Weisman, Michael Goldberg
-
Patent number: 7169765Abstract: The invention relates to compositions comprising acyl derivatives of 2?-deoxyribonucleosides. The invention also relates to methods of treating or preventing radiation, mutagen and sunlight-induced biological damage, and methods for improving wound healing and tissue repair, comprising administering the compositions of the present invention to an animal.Type: GrantFiled: January 31, 2000Date of Patent: January 30, 2007Assignee: Wellstat Therapeutics CorporationInventors: Reid W. Von Borstel, Michael K. Bamat
-
Patent number: 7164014Abstract: The invention features linker molecules that have at one terminus a amino-protecting group and at the other terminus a phosphorous activating group, typically phosphoramidite. The linker molecules can be used, for example, to produce amino-modified linkers that space an oligonucleotide from a solid support. The invention also features an amino-protected nucleotide that includes an activated phosphorous group such as a phosphoramidite for the production of a 5? amino-modified oligonucleotide. The invention further provides a phthalimido-modified support that can be used to synthesize a polynucleotide that includes an amino group at the 3? terminus.Type: GrantFiled: September 27, 2002Date of Patent: January 16, 2007Assignee: Linden Technologies, Inc.Inventors: Tai-Nang Huang, Ming Shen
-
Patent number: 7125983Abstract: A novel method has been found to produce 2,2?-anhydro-1-(?-L-arabinofuranosyl)thymine as a novel useful intermediate compound. A novel method has been further found to produce thymidine from 2,2?-anhydro-1-(?-L-arabinofuranosyl)thymine. A novel method has been further found to L-2?-deoxyribose derivatives as a useful synthetic intermediate through L-2,2?-anhydro-5,6-dihydrocyclouridine derivative. According to these methods, synthesis of various L-nucleic acid derivatives, synthesis of which has been difficult till now.Type: GrantFiled: November 29, 2001Date of Patent: October 24, 2006Assignee: Mitsui Chemicals, Inc.Inventors: Hajime Iizuka, Kazuhiko Togashi, Tsuneji Suzuki
-
Patent number: 7105498Abstract: The invention relates to compositions comprising acyl derivatives of cytidine and uridine. The invention also relates to methods of treating hepatopathies, diabetes, heart disease, cerebrovascular disorders, Parkinson's disease, infant respiratory distress syndrome and for enhancement of phospholipid biosynthesis comprising administering the acyl derivatives of the invention to an animal.Type: GrantFiled: September 28, 2001Date of Patent: September 12, 2006Assignee: Wellstat Therapeutics CorporationInventors: Reid Warren von Borstel, Michael Kevin Bamat
-
Patent number: 7084128Abstract: The present invention is directed to a method of reducing intraocular pressure. The method comprises administering to a subject a pharmaceutical composition comprising an effective amount of a purinerginic receptor ligand, which is a mononucleoside polyphosphate or dinucleoside polyphosphate defined by general Formula I. The method of the present invention is useful in the treatment or prevention of ocular hypertension, such as glaucoma, including primary and secondary glaucoma. The method can be used alone to reduce intraocular pressure. The method can also be used in conjunction with other therapeutic agents or adjunctive therapy commonly used to treat glaucoma to enhance the therapeutic effect of reducing the intraocular pressure.Type: GrantFiled: January 15, 2003Date of Patent: August 1, 2006Assignee: Inspire Pharmaceuticals, Inc.Inventors: Benjamin R. Yerxa, Robert Plourde, Jr., Edward G. Brown, Ward M. Peterson
-
Patent number: 7057033Abstract: The present invention concerns a new fractionated polydisperse carbohydrate composition having the following definition: an av. DP which is significantly higher than the av. DP of a native polydisperse carbohydrate composition, significantly free of low molecular monomers, dimmers, and oligomers, significantly free of impurities chosen among the group consisting of colourings, salts, proteins and organic acids, significantly free of technological aids such as solubility affecting products. The present invention concerns also the preparation process of the composition according to the invention.Type: GrantFiled: August 30, 2001Date of Patent: June 6, 2006Assignee: Tiense Suikerrafinaderij N.V.Inventors: Georges Smits, Luc Daenekindt, Karl Booten
-
Patent number: 7053199Abstract: Nucleoside analogues expressed by the following general formula where B represents an aromatic base having carbonyl oxygen at the 2-position, or a 2-hydroxyphenyl group, or oligonucleotide derivatives containing one or more of the nucleoside analogues are provided. The oligonucleotide derivatives are triplex-forming oligonucleotide derivatives which bind specifically to target double-stranded DNA with high affinity in the antigene method to form triplexes, and can thereby control and inhibit the expression of relevant genes efficiently, and which show high resistance to nucleases.Type: GrantFiled: August 29, 2001Date of Patent: May 30, 2006Inventors: Takeshi Imanishi, Satoshi Obika
-
Patent number: 7049432Abstract: The present invention provides alkylphosphonate dimers and oligonucleotides prepared therefrom. The invention further provides novel methods for the preparation of these alkylphosphonate dimers. Methods for the preparation of substantially diastereomerically pure alkylphosphonate dimers are also provided.Type: GrantFiled: June 4, 2002Date of Patent: May 23, 2006Assignees: ISIS Pharmaceuticals, Inc., McGill UniversityInventors: Muthiah Manoharan, George Just, Andrei Guzaev, Arlène Roland, Jianchao Wang, Michael E. Jung
-
Patent number: 7041655Abstract: In accordance with the invention there is provided a method of treating a human subject to prevent leakage of serum proteins from capillary endothelial junctions during a period of increased capillary permeability. The invention also provides a method for preventing the harmful effects of free radicals on cellular membranes and other organelles. The method comprises administering to a subject an effective amount of a composition comprising at least one polysaccharide selected from the group consisting of hydroxyethyl starch and dextran of varying molecular sizes and at least one member of the group consisting of superoxide dismutase, glutathione peroxidase, catalase, hydroxyethyl rutoside, cyclic adenosine monophosphate and vitamin C. The compositions contain the macromolecules in a molecular size and concentration to effectively stabilize the capillary membrane.Type: GrantFiled: April 22, 1997Date of Patent: May 9, 2006Inventors: Bashir Zikria, Jemal D. Zikria
-
Patent number: 7034147Abstract: The present invention provides combinatorial libraries of nucleoside analog compounds and methods of making the libraries. In addition, the present invention provides methods of assaying the libraries for agonists or antagonists of a broad array of targets of therapeutic importance.Type: GrantFiled: May 8, 2003Date of Patent: April 25, 2006Assignee: IRM LLCInventors: Robert Epple, William Greenberg, Romas Kudirka
-
Patent number: 7026469Abstract: The invention includes compositions and methods useful for treatment of a virus infection in a mammal by double-targeting the virus (i.e. targeting the virus at more than one stage of the virus life cycle) and thereby inhibiting virus replication. The compositions of the invention include compounds, which comprise a phosphocholine moiety covalently conjugated with one or more therapeutic agents (e.g. nucleoside analogue, protease inhibitor, etc.) to a lipid backbone. The invention also includes pharmaceutical compositions for use in treatment of a virus infection in mammals. The methods of the invention comprise administering a compound of the invention, a pharmaceutically acceptable salt or a prodrug thereof, or a pharmaceutical composition of the invention, in an amount effective to treat the infection, to a mammal infected with a virus.Type: GrantFiled: April 27, 2001Date of Patent: April 11, 2006Assignees: Wake Forest University School of Medicine, University of North Carolina at ChapelInventors: Louis S. Kucera, Ronald A. Fleming, Khalid S. Ishaq, Gregory L. Kucera, Susan L. Morris-Natschke
-
Patent number: 7026468Abstract: A scalable alkaline lysis process, including procedures and devices for the isolation of large quantities (grams and kilograms) of plasmid DNA from recombinant E. coli cell. Effective, contgrollable, and economical operation, and consistent low level of host chromosomal DNA in the final plasmid product. Involves a series of new unit operations and devices for cell resuspension, cell lysis, and nuetralization.Type: GrantFiled: January 29, 2001Date of Patent: April 11, 2006Assignee: Valentis, Inc.Inventors: Samuel Nochumson, Ross Durland, Audrey Yu-Speight, John Welp, Kuoewi Wu, Rexford Hayes
-
Patent number: 7022833Abstract: A process for the synthesis of a phosphorothioate triester is provided. The process comprises the coupling of an H-phosphonate with an alcohol in the presence of a solution comprising both a coupling agent and a sulfur transfer agent. Preferably, the H-phosphonate and alcohol are protected nucleosides or oligonucleotides.Type: GrantFiled: February 23, 2001Date of Patent: April 4, 2006Assignee: Avecia LimitedInventor: Colin Bernard Reese
-
Patent number: 7018985Abstract: The present invention provides novel compounds of dinucleotide polyphosphates and the method of preventing or treating diseases or conditions associated with platelet aggregation. The method comprises administering systemically to a patient a pharmaceutical comprising a purinergic P2? receptor antagonist, in an amount effective to elevate its extracellular concentration to bind to P2? receptors and inhibit P2? receptor-mediated platelet aggregation. Methods of systemic administration include injection by intravenous, intramuscular, intrasternal and intravitreal routes, infusion, transdermal administration, oral administration, rectal administration and intra-operative instillation.Type: GrantFiled: August 21, 2000Date of Patent: March 28, 2006Assignees: Inspire Pharmaceuticals, Inc., University of North Carolina at Chapel HillInventors: José L. Boyer, Gillian M. Olins, Benjamin R. Yerxa, James G. Douglass, III
-
Patent number: 7009046Abstract: Provided is an agent serving as a binder and a disintegrant for dry direct compression having a high binding property and fluidity. More specifically, provided are low-substituted hydroxypropyl cellulose having coiled fibers; an agent serving both as a binder and a disintegrant for dry direct compression and a solid preparation, each comprising the low-substituted hydroxypropyl cellulose; and a process for producing the low-substituted hydroxypropyl cellulose having coiled fibers.Type: GrantFiled: December 10, 2002Date of Patent: March 7, 2006Assignee: Shin-Etsu Chemical Co. Ltd.Inventors: Naosuke Maruyama, Hiroshi Umezawa
-
Patent number: 7002006Abstract: A process of manufacturing protected nucleosides comprises reacting a nucleoside with a protecting reagent in the presence of a regioselective activator to produce a regioselectively protected nucleoside. In some embodiments of the inventive method, an optionally substituted trityl or optionally substituted pixyl group is selectively added to the 5?-O-position of a nucleoside in the presence of lutidine as activator or activator/solvent. The inventive method results in improved selectivity of the 5?-O-position over the 3?-O-position, thereby improving overall product yield and purity, and permitting simplified purification protocols, in some cases obviating the need for chromatography to produce a purified protected nucleoside suitable for automated synthesis of oligonucleotides, such as primers, probes and antisense molecules.Type: GrantFiled: February 12, 2003Date of Patent: February 21, 2006Assignee: ISIS Pharmaceuticals, Inc.Inventors: Quanlai Song, Bruce S. Ross
-
Patent number: 6987125Abstract: Compositions and methods for the treatment, reduction and/or prevention of cardiovascular diseases and disorders are described. Individuals at high risk for developing or having cardiovascular disease or disorder may be treated with an effective dose of a polymethoxyflavone including limocitrin derivatives, quercetin derivatives, naturally occurring polymethoxyflavones, tocotrienols, and mixtures of these compounds.Type: GrantFiled: March 17, 2000Date of Patent: January 17, 2006Assignee: The United States of America as represented by the Secretary of AgricultureInventors: Najla Guthrie, Elzbieta Maria Kurowska, John A. Manthey, Sylvia Horowitz, Robert M. Horowitz
-
Patent number: 6984629Abstract: Based on research for compounds that can display a corneal epithelial migration promoting effect in ophthalmology, the present invention provides P2Y receptor agonist corneal epithelial migration promoters, such as phosphoric acid compounds having an adenosyl group, uridyl group, xanthosyl group, guanosyl group, or thymidyl group, or their salts, with excellent corneal epithelial migration promoting effects.Type: GrantFiled: May 30, 2001Date of Patent: January 10, 2006Assignees: Santen Pharmaceutical Co., Ltd., Inspire Pharmaceuticals, Inc.Inventors: Katsuhiko Nakata, Masatsugu Nakamura, Tsutomu Fujihara, Hiromi Fujita
-
Patent number: RE39464Abstract: Novel chiral compounds that mimic and/or modulate the activity of wild-type nucleic acids are disclosed. In general, the compounds are phosphorothioate oligonucleotides wherein the 5?, and the 3?-terminal internucleoside linkages are chirally Sp and internal internucleoside linkages are chirally Rp.Type: GrantFiled: August 24, 2004Date of Patent: January 9, 2007Assignee: ISIS Pharmaceuticals Inc.Inventors: Phillip Dan Cook, Muthiah Manoharan